Cargando…
Labeling Cell Surface Receptors with Ligand.BirA* Bispecifics
[Image: see text] BirA*, a mutant form of the biotinylating enzyme BirA, can nonspecifically biotinylate ε-amino groups on lysines of proteins. Based on the promiscuous labeling nature of BirA*, plasmids expressing fusion constructs of BirA* to a given ligand have been used to transfect eukaryotic c...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890520/ https://www.ncbi.nlm.nih.gov/pubmed/36742360 http://dx.doi.org/10.1021/acsptsci.1c00192 |
_version_ | 1784880960180846592 |
---|---|
author | Alwash, Mays Gariépy, Jean |
author_facet | Alwash, Mays Gariépy, Jean |
author_sort | Alwash, Mays |
collection | PubMed |
description | [Image: see text] BirA*, a mutant form of the biotinylating enzyme BirA, can nonspecifically biotinylate ε-amino groups on lysines of proteins. Based on the promiscuous labeling nature of BirA*, plasmids expressing fusion constructs of BirA* to a given ligand have been used to transfect eukaryotic cells, leading to the biotinylation of intracellular proteins interacting or in close proximity to such Ligand.BirA* constructs. Mass spectrometry performed on the recovered biotinylated partners allows one to map intracellular protein interactors, a technique known as BioID. In contrast, the expression and purification of recombinant Ligand.BirA* constructs could serve as a powerful tool for labeling and detecting cell surface receptors. Here, we report the design and expression of recombinant Affibody.BirA* constructs, Z(EGFR:1907).BirA* and Z(HER2:243).BirA*, as protein bispecifics able to biotinylate their respective receptors EGFR and HER2 on the surface of MDA-MB-231 (EGFR(+), EpCaM(+), and CD44(+)) and SK-OV-3 (HER2(++), EGFR(+), EpCaM(+), and CD44(+)) cancer cells. These Affibody.BirA* constructs retain both their BirA* enzymatic activity as well as their receptor-binding function. Importantly, MDA-MB-231 and SK-OV-3 cells biotinylated with Affibody.BirA* constructs did label their receptors EGFR and HER2 but did not biotinylate irrelevant antigens such as EpCaM or CD44 present on the surface of both cell lines. Ligand.BirA* bispecifics may represent a promising class of agents to identify unknown receptors on cell surfaces. |
format | Online Article Text |
id | pubmed-9890520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-98905202023-02-02 Labeling Cell Surface Receptors with Ligand.BirA* Bispecifics Alwash, Mays Gariépy, Jean ACS Pharmacol Transl Sci [Image: see text] BirA*, a mutant form of the biotinylating enzyme BirA, can nonspecifically biotinylate ε-amino groups on lysines of proteins. Based on the promiscuous labeling nature of BirA*, plasmids expressing fusion constructs of BirA* to a given ligand have been used to transfect eukaryotic cells, leading to the biotinylation of intracellular proteins interacting or in close proximity to such Ligand.BirA* constructs. Mass spectrometry performed on the recovered biotinylated partners allows one to map intracellular protein interactors, a technique known as BioID. In contrast, the expression and purification of recombinant Ligand.BirA* constructs could serve as a powerful tool for labeling and detecting cell surface receptors. Here, we report the design and expression of recombinant Affibody.BirA* constructs, Z(EGFR:1907).BirA* and Z(HER2:243).BirA*, as protein bispecifics able to biotinylate their respective receptors EGFR and HER2 on the surface of MDA-MB-231 (EGFR(+), EpCaM(+), and CD44(+)) and SK-OV-3 (HER2(++), EGFR(+), EpCaM(+), and CD44(+)) cancer cells. These Affibody.BirA* constructs retain both their BirA* enzymatic activity as well as their receptor-binding function. Importantly, MDA-MB-231 and SK-OV-3 cells biotinylated with Affibody.BirA* constructs did label their receptors EGFR and HER2 but did not biotinylate irrelevant antigens such as EpCaM or CD44 present on the surface of both cell lines. Ligand.BirA* bispecifics may represent a promising class of agents to identify unknown receptors on cell surfaces. American Chemical Society 2022-02-01 /pmc/articles/PMC9890520/ /pubmed/36742360 http://dx.doi.org/10.1021/acsptsci.1c00192 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Alwash, Mays Gariépy, Jean Labeling Cell Surface Receptors with Ligand.BirA* Bispecifics |
title | Labeling Cell Surface Receptors with Ligand.BirA*
Bispecifics |
title_full | Labeling Cell Surface Receptors with Ligand.BirA*
Bispecifics |
title_fullStr | Labeling Cell Surface Receptors with Ligand.BirA*
Bispecifics |
title_full_unstemmed | Labeling Cell Surface Receptors with Ligand.BirA*
Bispecifics |
title_short | Labeling Cell Surface Receptors with Ligand.BirA*
Bispecifics |
title_sort | labeling cell surface receptors with ligand.bira*
bispecifics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890520/ https://www.ncbi.nlm.nih.gov/pubmed/36742360 http://dx.doi.org/10.1021/acsptsci.1c00192 |
work_keys_str_mv | AT alwashmays labelingcellsurfacereceptorswithligandbirabispecifics AT gariepyjean labelingcellsurfacereceptorswithligandbirabispecifics |